DK2804587T3 - Formulering og fremgangsmåde til øgning af lægemidlers biotilgængelighed - Google Patents

Formulering og fremgangsmåde til øgning af lægemidlers biotilgængelighed Download PDF

Info

Publication number
DK2804587T3
DK2804587T3 DK13703152.2T DK13703152T DK2804587T3 DK 2804587 T3 DK2804587 T3 DK 2804587T3 DK 13703152 T DK13703152 T DK 13703152T DK 2804587 T3 DK2804587 T3 DK 2804587T3
Authority
DK
Denmark
Prior art keywords
biodeless
pharmaceuticals
formulation
procedure
increasing
Prior art date
Application number
DK13703152.2T
Other languages
English (en)
Inventor
Amnon Hoffman
Anna Elgart
Irina Cherniakov
Abraham J Domb
Original Assignee
Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd filed Critical Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd
Application granted granted Critical
Publication of DK2804587T3 publication Critical patent/DK2804587T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5123Organic compounds, e.g. fats, sugars
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/17Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/366Lactones having six-membered rings, e.g. delta-lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/658Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/67Piperaceae (Pepper family), e.g. Jamaican pepper or kava
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK13703152.2T 2012-01-19 2013-01-17 Formulering og fremgangsmåde til øgning af lægemidlers biotilgængelighed DK2804587T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261588341P 2012-01-19 2012-01-19
US201261615457P 2012-03-26 2012-03-26
US201261696540P 2012-09-04 2012-09-04
US201261704893P 2012-09-24 2012-09-24
PCT/IL2013/050047 WO2013108254A1 (en) 2012-01-19 2013-01-17 Formulation and method for increasing oral bioavailability of drugs

Publications (1)

Publication Number Publication Date
DK2804587T3 true DK2804587T3 (da) 2019-08-12

Family

ID=47678957

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13703152.2T DK2804587T3 (da) 2012-01-19 2013-01-17 Formulering og fremgangsmåde til øgning af lægemidlers biotilgængelighed

Country Status (5)

Country Link
US (3) US20140348926A1 (da)
EP (1) EP2804587B1 (da)
DK (1) DK2804587T3 (da)
ES (1) ES2739194T3 (da)
WO (1) WO2013108254A1 (da)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX374014B (es) 2012-05-16 2020-07-24 Mewa Singh Composiciones farmaceuticas para la entrega de farmacos insolubles en agua.
CA3002989C (en) 2013-10-14 2021-03-16 Nanosphere Health Sciences, Llc Nanoparticle compositions and methods as carriers of nutraceutical factors across cell membranes and biological barriers
WO2015118549A1 (en) * 2014-02-10 2015-08-13 F&C Licorice Ltd. Encapsulated biologically active agents
WO2015171445A1 (en) * 2014-05-06 2015-11-12 Mewa Singh Pharmaceutical compositions comprising hemp and turmeric to treat pain and inflammation
EP3193862B1 (en) 2014-09-16 2023-10-18 Igc Pharma Ip, Llc Topical cannabinoid composition for treating arthritic pain
US10350165B2 (en) 2014-12-12 2019-07-16 Ojai Energetics Pbc Methods and systems for forming stable droplets
JP2018505912A (ja) * 2014-12-12 2018-03-01 オーハイ エナジェティクス ピービーシー マイクロカプセル化カンナビノイド組成物
US11707436B2 (en) 2014-12-15 2023-07-25 Nanosphere Health Sciences Inc. Methods of treating inflammatory disorders and global inflammation with compositions comprising phospholipid nanoparticle encapsulations of NSAIDS
US10751300B2 (en) 2015-01-25 2020-08-25 India Globalization Capital, Inc. Composition and method for treating seizure disorders
CA2979184C (en) 2015-03-10 2020-09-08 Nanosphere Health Sciences, Llc Lipid nanoparticle compositions and methods as carriers of cannabinoids in standardized precision-metered dosage forms
US10596159B2 (en) 2015-08-12 2020-03-24 India Globalization Capital, Inc. Method and composition for treating cachexia and eating disorders
CA2995158C (en) 2015-08-28 2021-05-11 Caliway Biopharmaceuticals Co., Ltd. A pharmaceutical composition for reducing local fat and uses thereof
EP3368014B1 (en) 2015-10-26 2023-10-04 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd Novel cannabinoid formulations
WO2017074266A1 (en) * 2015-10-30 2017-05-04 National University Of Singapore Androgen biosynthesis inhibitor
EP3251668A1 (en) 2016-06-02 2017-12-06 Pharmotech SA Cannabidiol compositions and uses thereof
CA3027862A1 (en) 2016-06-15 2017-12-21 India Globalization Capital, Inc. Method and composition for treating seizure disorders
EP3290026A1 (en) 2016-09-06 2018-03-07 Athenion AG Method for solubilizing poorly water-soluble dietary supplements and pharmaceutically active agents
IL248150B (en) 2016-09-29 2018-05-31 Garti Nissim Method for selective extraction of cannabinoids from a plant source
IL248149B (en) * 2016-09-29 2020-03-31 Garti Nissim Formulations of dilutable cannabinoids and processes for their preparation
US10835501B2 (en) * 2016-10-01 2020-11-17 Indication Bioscience Llc Pharmaceutical compositions comprising a statin and a cannabinoid and uses thereof
ES2979135T3 (es) * 2016-10-14 2024-09-24 Cipla Ltd Composiciones farmacéuticas que comprenden rifaximina
US20180169061A1 (en) * 2016-12-15 2018-06-21 Ascent Pharmaceuticals, Inc. Non-aqueous delta9-tetrahydrocannabinol oral liquid formulations
CA3053158A1 (en) * 2017-02-15 2018-08-23 Molecular Infusions, Llc Formulations
EP3684794B1 (en) 2017-09-19 2025-08-06 Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. Somatostatin prodrugs
EP3511325A1 (en) 2018-01-11 2019-07-17 MetrioPharm AG Method for solubilizing 5-amino-2,3-dihydro-1,4-phthalazinedione
EP3536332A1 (en) 2018-03-07 2019-09-11 Athenion AG Krill oil for solubilizing poorly water-soluble dietary supplements and pharmaceutically active agents
IL261132A (en) 2018-08-13 2018-11-04 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof
SG11202106144VA (en) 2018-12-11 2021-07-29 Disruption Labs Inc Compositions for the delivery of therapeutic agents and methods of use and making thereof
CN111632052A (zh) * 2019-03-01 2020-09-08 沈阳药科大学 胡椒碱在制备sEH抑制剂中的应用
US20200375911A1 (en) * 2019-06-03 2020-12-03 Fresh Cut Development, Llc Cannabidiol nanocrystal compositions
WO2021046189A1 (en) * 2019-09-06 2021-03-11 Quicksilver Scientific, Inc. Microemulsion delivery systems for water-based beverages
US11123291B2 (en) 2019-09-12 2021-09-21 Nulixir Inc. Methods and systems for forming multi-layered particles
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
CA3156257A1 (en) 2019-10-03 2021-04-08 Starton Therapeutics, Inc. TRANSDERMAL DELIVERY OF DRONABINOL
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12186280B2 (en) 2019-10-11 2025-01-07 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
MX2022004258A (es) 2019-10-14 2022-05-26 Pike Therapeutics Inc Entrega transdermica de cannabidiol.
US11872197B2 (en) 2020-03-03 2024-01-16 Another Chance Nutra, LLC Method of treatment or alleviating symptoms of a disorder with curcumin
EP4114362A4 (en) * 2020-03-05 2024-03-20 University of Miami NANODRUG FORMULATIONS OF CANNABIDIOL AND THEIR METHODS OF USE
EP3919046A1 (en) 2020-06-02 2021-12-08 Athenion AG Method for solubilizing natural, endogenous and synthetic cannabinoids
AU2021307693A1 (en) * 2020-07-15 2023-02-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Oral cavity polymeric delivery systems
US20230345992A1 (en) 2020-07-29 2023-11-02 Karnak Technologies, Llc Oral compositions of lipophilic diety supplements, nutraceuticals and beneficial edible oils
EP4188334A1 (en) 2020-07-29 2023-06-07 Karnak Technologies, LLC Pharmaceutical compositions for improved delivery of therapeutic lipophilic actives
WO2022211481A1 (ko) 2021-04-01 2022-10-06 에스엔제이 파마 인크 생활성물질의 경구용 나노입자 및 이의 제조방법
US20220347119A1 (en) * 2021-04-30 2022-11-03 Reshma N. Kheraj Medicated drink
EP4396162A4 (en) 2021-09-03 2025-11-12 Alexander Shulgin Res Institute Inc ASYMMETRIC ALLYL TRYPTAMINES
WO2023043854A1 (en) * 2021-09-14 2023-03-23 Nulixir Inc. Alimentary-related particles, production methods, and production apparatus
IL311647A (en) 2021-09-25 2024-05-01 Alexander Shulgin Res Institute Inc Converted phenylalkylamines
EP4186497A1 (en) 2021-11-26 2023-05-31 Dorian Bevec Alpha lipoic acid, epigallocatechin 3-gallate, and curcumin as a medicament for the treatment of arthritis or sars-cov-2 infection
LU501323B1 (en) 2022-01-25 2023-07-25 Kemijski Inst Cannabinoid complexes with improved properties
IT202200025767A1 (it) 2022-12-15 2024-06-15 Prolabin & Tefarm S R L Formulazione comprendente polifenoli vanilloidi supportati su solidi lamellari per ridurre i livelli plasmatici di CGRP e sue applicazioni.

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816247A (en) * 1985-09-11 1989-03-28 American Cyanamid Company Emulsion compositions for administration of sparingly water soluble ionizable hydrophobic drugs
IN176897B (da) 1993-10-29 1996-09-28 Cadila Lab Ltd
EP0650728B1 (en) 1993-10-29 2002-02-27 Council of Scientific and Industrial Research Pharmaceutical compositions containing piperine and an antituberculosis or antileprosydrug
US5744161A (en) 1995-02-24 1998-04-28 Sabinsa Corporation Use of piperine as a bioavailability enhancer
US5536506A (en) 1995-02-24 1996-07-16 Sabinsa Corporation Use of piperine to increase the bioavailability of nutritional compounds
US20070160675A1 (en) * 1998-11-02 2007-07-12 Elan Corporation, Plc Nanoparticulate and controlled release compositions comprising a cephalosporin
US7919113B2 (en) 1999-12-30 2011-04-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Dispersible concentrate lipospheres for delivery of active agents
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
WO2003049753A1 (en) 2001-12-13 2003-06-19 Council Of Scientific And Industrial Research Bioavailability enhancing activity of zingiber officinale linn and its extracts/fractions thereof
US20060148727A1 (en) * 2004-12-01 2006-07-06 Curt Hendrix Folate based composition for neurological and cognitive applications
JP2009514890A (ja) * 2005-11-07 2009-04-09 マーティ・ファーマシューティカルズ・インク テトラヒドロカンナビノールの改良された送達
US9192644B2 (en) * 2006-03-06 2015-11-24 The Regents Of The University Of California Bioavailable curcuminoid formulations for treating Alzheimer's disease and other age-related disorders
US10960077B2 (en) * 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
GB0623838D0 (en) 2006-11-29 2007-01-10 Malvern Cosmeceutics Ltd Novel compositions
EP1938801A1 (en) 2006-12-22 2008-07-02 Biofrontera Bioscience GmbH Nanoemulsion
US20100160450A1 (en) 2007-01-31 2010-06-24 Eric Kuhrts Methods of reducing 15-f2t-isop levels in mammals
US8101274B2 (en) 2007-06-11 2012-01-24 Spedden Richard H Solid state membranes with surface-embedded glycosylated amphiphilic molecules and micelles formed therefrom
WO2009052491A2 (en) 2007-10-18 2009-04-23 Geraghty, Erin Fenoldopam formulations and prodrug derivatives
WO2010010431A1 (en) * 2008-07-24 2010-01-28 National Institute Of Pharmaceutical Education And Research Self-nano-emulsifying curcuminoids composition with enhanced bioavailability
WO2010019255A1 (en) * 2008-08-13 2010-02-18 Virun, Inc. Compositions containing aminoalkanes and aminoalkane derivatives
IT1395086B1 (it) 2009-03-11 2012-09-05 Velleja Res Srl Composizioni comprendenti curcumina in forma complessata con fosfolipidi e piperina ad azione chemio-sensibilizzante
EP3295794A1 (en) 2010-07-27 2018-03-21 Flex Pharma, Inc. Methods and compositions for preventing and relieving muscle cramps and for recovery from neuromuscular irritability and fatigue following exercise
JP5868414B2 (ja) * 2010-11-08 2016-02-24 カディラ ファーマシューティカルズ リミテッド タキソイドの医薬組成物
KR102213143B1 (ko) * 2013-02-28 2021-02-08 바스프 에이에스 지방질 화합물, 트리글리세리드 및 계면활성제를 포함하는 조성물 및 이를 이용하는 방법

Also Published As

Publication number Publication date
EP2804587A1 (en) 2014-11-26
US20240335391A1 (en) 2024-10-10
US20140348926A1 (en) 2014-11-27
EP2804587B1 (en) 2019-05-08
US12161763B2 (en) 2024-12-10
US20200009067A1 (en) 2020-01-09
ES2739194T3 (es) 2020-01-29
WO2013108254A1 (en) 2013-07-25

Similar Documents

Publication Publication Date Title
DK2804587T3 (da) Formulering og fremgangsmåde til øgning af lægemidlers biotilgængelighed
DK3238709T3 (da) Forbedrede parenterale formuleringer af lipofile farmaceutiske midler og fremgangsmåder til fremstilling og anvendelse af samme
DK2898061T3 (da) Probiotiske sammensætninger til behandlingen af fedme og fedme-relaterede tilstande
DK2903600T3 (da) Virusholdig formulering og anvendelse deraf
DK2800565T3 (da) Carbamatforbindelser og fremgangsmåder til fremstilling og anvendelse af samme
DK3550836T3 (da) Fremgangsmåde og anordning til afkodning
DK3608325T3 (da) Polycykliske-carbamoylpyridonforbindelser og deres farmaceutiske anvendelse
DK2929031T5 (da) Pcsk9-irna-sammensætninger og fremgangsmåder til anvendelse deraf
HUE040111T2 (hu) Vegyületek és alkalmazási eljárásaik
EP2930714A4 (en) Singing voice synthesizing system and singing voice synthesizing method
DK2854883T3 (da) Biomatrix-hydrogeler og fremgangsmåder til anvendelse deraf
DK3777840T3 (da) Rna-formulering til immunterapi
DK2920149T3 (da) 3-aminocycloalkyl-forbindelser som ror-gamma-t-inhibitorer og anvendelser deraf
DK2838533T3 (da) Sammensætninger og fremgangsmåder til at modulere 15-pgdh-aktivitet
DK2892912T3 (da) C17-alkandiyl og alkenediylderivater af oleanolsyre og fremgangsmåder til anvendelse deraf
DK2919923T3 (da) Holder-sortiment og rengøringsapparater til rengøring af åndedrætsapparater
DK2729151T3 (da) Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf
DK3050883T3 (da) Fremgangsmåde til fremstilling af diazabicyclooctanderivater og mellemprodukter
DK3080281T3 (da) System til administration af mikrobiske inokulanter og relaterede materialer og fremgangsmåder
DK2867422T3 (da) Anordning til armering af sammenføjninger og søjler i kombination
DK3049059T3 (da) Intranasal dhe formulering til behandlingen af hovedpine
DK2836460T3 (da) Fremgangsmåde til fremstilling af graphen
DK3010895T3 (da) Fremgangsmåde til fremstilling af 4-propargyleret aminobenzoxazinoner
DK2964767T3 (da) Toksingener og fremgangsmåder til anvendelse deraf
DK2922860T3 (da) Hydrerede og vandfri polymorfer af 2&#39;-o-fucosyllactose samt fremgangsmåder til fremstilling deraf